Australia approves new Pfizer COVID booster targeting the JN.1 sub-variant of Omicron.

Australia's Therapeutic Goods Administration has approved a new Pfizer COVID booster targeting the JN.1 sub-variant of Omicron. This is the fifth vaccine update, using mRNA technology to help the immune system produce antibodies against the virus's evolving spike protein. Booster schedules vary by age: adults 65-74 should consider a booster every 12 months, those over 75 every 6 months, and adults 18-64 annually, with exceptions for immune deficiencies. The new boosters are expected to roll out soon, offering better protection against upcoming Omicron sub-variants.

November 17, 2024
63 Articles